News New heart attack data boost AZ’s Brilinta A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients.
News Akebia joins GSK in US market for oral CKD anaemia drugs The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS
Digital Sponsored Innovation as Strategy: Enabling life sciences of the future Explore “Innovation as Strategy” framework, providing a guide for employing innovative strategies in life sciences.